Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.44 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.39 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23982307 | 0.87 | PRMT5 (0.47) | PRMT5WDR77ADK | |
| SCHEMBL20419326 | 0.87 | PRMT5 (0.47) | PRMT5WDR77ADK | |
| SCHEMBL20419292 | 0.87 | PRMT5 (0.47) | PRMT5WDR77ADK | |
| SCHEMBL19187629 | 0.86 | ADK (0.54) | PRMT5WDR77METTL3ADK | |
| SCHEMBL14228171 | 0.86 | ADK (0.54) | PRMT5WDR77METTL3ADK | |
| SCHEMBL20692015 | 0.86 | PRMT5 (0.44) | PRMT5WDR77METTL3METTL14ADK | |
| SCHEMBL10067814 | 0.86 | ADK (0.54) | PRMT5WDR77METTL3ADK | |
| SCHEMBL14544365 | 0.84 | PRMT5 (0.52) | PRMT5WDR77METTL3METTL14ADK | |
| SCHEMBL27786166 | 0.83 | PRMT5 (0.42) | PRMT5WDR77METTL3METTL14ADK | |
| SCHEMBL14544374 | 0.81 | ADK (0.44) | PRMT5WDR77METTL3METTL14ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629328-B2 | Nucleoside derivatives for treating hepatitis C virus infection | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090036399-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. | 2009-02-05 | — | — | US | disclosed |
| US-7432248-B2 | Nucleoside derivatives for treating Hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036399-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | HAVCR2, PNP, NSUN2 | PRMT5 1058/4885WDR77 2426/4885METTL3 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.